Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11291275 | 0.87 | HDAC8 (0.55) | POLBHPGDALDH1A1HDAC8HDAC6 | |
| SCHEMBL7056987 | 0.84 | HDAC8 (0.67) | POLBHPGDALDH1A1HDAC8HDAC6 | |
| SCHEMBL5808330 | 0.84 | POLB (0.61) | POLBHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL1793321 | 0.84 | POLB (0.45) | POLBHPGDALDH1A1HDAC8HDAC6 | |
| SCHEMBL21597725 | 0.82 | — | — | |
| SCHEMBL3719107 | 0.82 | — | — | |
| SCHEMBL23107334 | 0.80 | — | — | |
| SCHEMBL3264706 | 0.78 | — | — | |
| SCHEMBL21603864 | 0.78 | — | — | |
| SCHEMBL20162014 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516423-A1 | THIENYLPYRI (MI) DINYLAZOLE AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI | Bayer CropScience AG (DE) | 2012-10-31 | — | — | EP | claimed |
| US-20110237588-A1 | Thienylpyri(mi)dinylazole | BAYER CROPSCIENCE AG (DE) | 2011-09-29 | — | — | US | claimed |
| WO-2011076725-A1 | THIENYLPYRI (MI) DINYLAZOLE AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-06-30 | — | — | WO | claimed |
| CN-117321059-A | Tetracyclic compounds for the treatment of Zika virus infection | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| WO-2019228289-A1 | SUBSTITUTED OXADIAZOLE COMPOUND AND APPLICATION THEREOF | 沈阳化工大学 (CN) | 2019-12-05 | — | — | WO | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-2738170-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9156837-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20110237588-A1 | Thienylpyri(mi)dinylazole | BAYER CROPSCIENCE AG (DE) | 2011-09-29 | — | — | US | disclosed |
| CN-102124005-A | Cmet inhibitors | TAKEDA PHARMACEUTICAL | 2011-07-13 | — | — | CN | disclosed |
| WO-2011076725-A1 | THIENYLPYRI (MI) DINYLAZOLE AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-06-30 | — | — | WO | disclosed |
| EP-2313407-A1 | cMET INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20110034445-A1 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189785-B2 | Heterocyclic compound | SPTLC1, SPTLC2, NPC1 | POLB 2845/4885HPGD 875/4885ALDH1A1 2775/4885 |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | MAPK13, MMP13, MAPK3 | POLB 1293/4885HPGD 337/4885ALDH1A1 3657/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | POLB 2449/4885HPGD 2599/4885ALDH1A1 3166/4885 |
| US-20110034445-A1 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES | HAAO, HPD, CYP51A1 | POLB 4390/4885HPGD 373/4885ALDH1A1 2550/4885 |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | SPTLC1, SPTLC2, NPC1 | POLB 2845/4885HPGD 875/4885ALDH1A1 2775/4885 |
| US-20110237588-A1 | Thienylpyri(mi)dinylazole | PADI1, TH, H1-3 | POLB 2935/4885HPGD 3111/4885ALDH1A1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.